Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

<p>Supp Tables</p>

Salvato in:

Dettagli Bibliografici
Autore principale:	Renumathy Dhanasekaran (14962092) (author)
Altri autori:	Aida S. Hansen (14962095) (author), Jangho Park (14962098) (author), Lea Lemaitre (14962101) (author), Ian Lai (14962104) (author), Nia Adeniji (14962107) (author), Sibu Kuruvilla (14962110) (author), Akanksha Suresh (14962113) (author), Josephine Zhang (14962116) (author), Varsha Swamy (14962119) (author), Dean W. Felsher (14962122) (author)
Pubblicazione:	2025
Soggetti:	Cancer Cancer Biology Immuno-oncology Immunology Immune responses to cancer Tumor-associated macrophages Immunotherapy Checkpoint blockade Combination immunotherapy Oncogenes & Tumor Suppressors Oncogenes
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
di: Hansol Lee (15054787)
Pubblicazione: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
di: Hansol Lee (15054787)
Pubblicazione: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
di: Hansol Lee (15054787)
Pubblicazione: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
di: Hansol Lee (15054787)
Pubblicazione: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
di: Xufeng Lu (14960724)
Pubblicazione: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
di: Francisco Exposito (16721403)
Pubblicazione: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
di: Xiaodong Shu (16721586)
Pubblicazione: (2025)

Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supplementary Table S3 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
di: Shima Nakanishi (16336496)
Pubblicazione: (2025)

Supplementary Table S4 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
di: Shima Nakanishi (16336496)
Pubblicazione: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
di: Duygu Kuzuoglu-Ozturk (14960213)
Pubblicazione: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
di: Duygu Kuzuoglu-Ozturk (14960213)
Pubblicazione: (2025)

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
di: Duygu Kuzuoglu-Ozturk (14960213)
Pubblicazione: (2025)

Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
di: Renzo Perales-Linares (17314863)
Pubblicazione: (2025)

Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations
di: Yuxi Liu (15293121)
Pubblicazione: (2025)

Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx
di: Soyoung Kim (117362)
Pubblicazione: (2025)

Supplementary Tables from The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
di: Jing Tang (17314958)
Pubblicazione: (2025)

Cannot write session to /tmp/vufind_sessions/sess_hkl671gik99ger5epdnq1h85kg